The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 54.50
Bid: 53.00
Ask: 56.00
Change: 0.00 (0.00%)
Spread: 3.00 (5.66%)
Open: 54.50
High: 54.50
Low: 54.50
Prev. Close: 54.50
MYX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

5 Jun 2015 07:00

RNS Number : 3111P
MyCelx Technologies Corporation
05 June 2015
 



5 June 2015

 

MyCelx Technologies Corporation

("MyCelx" or the "Company" (AIM: MYX))

 

Dealing by Directors

 

The Company announces that on 3 June 2015, Tim Eggar, Chairman and a Director of the Company, notified the Company that he had exercised options over 50,459 common shares of US$0.025 each ("Common Shares") under the Company's Omnibus Performance Incentive Plan 2011 (the "Plan") at a price of US$0.86 per Common Share.

 

Following this transaction, Mr Eggar now holds 130,679 Common Shares, representing 0.70 per cent of the increased issued capital of the Company.

 

The Company further announces that on 3 June 2015, Brian Rochester, a Director of the Company, notified the Company that he had exercised options over 41,143 Common Shares under the Plan at a price of US$0.86 per Common Share.

 

Following this transaction, Mr Rochester now holds 41,143 Common Shares, representing 0.22 per cent of the increased issued capital of the Company. R. Bros. Investments LLC, in which Mr Rochester holds a 50% interest, also holds 191,305 Common Shares representing 1.02 per cent of the increased issued capital of the Company. Mrs Alana Rochester, Mr Rochester's wife, also holds 32,044 Common Shares, representing 0.17 per cent of the increased issued capital of the Company.

 

Exercise of Share Option by Significant Shareholder

 

The Company further announces that on 3 June 2015, John Mansfield Sr., Chairman Emeritus and co-founder of the Company and a former Director of the Company, notified the Company that he had exercised an option over 54,340 Common Shares under the Plan at a price of US$0.86 per Common Share. In accordance with the provisions of the Plan, the subscription price for 32,296 Common Shares forming part of this option was settled by the cancellation of the balance of 22,044 Common Shares, based on the market value of the Common Shares at the time of exercise.

 

Following this transaction, Mr Mansfield now holds 1,703,380 Common shares, representing 9.07 per cent of the increased issued capital of the Company. This aggregate number of shares includes a holding by Mansfield Holdings LLC, a limited liability company controlled by Mr Mansfield, of 205,082 Common Shares representing 1.09 per cent of the increased issued capital of the Company.

 

Exercise of Share Option

 

The Company further announces that on 3 June 2015, an option over 24,065 Common Shares under the Plan was exercised by a former director at a price of US$0.86 per Common Share. In accordance with the provisions of the Plan, the subscription price for 14,439 Common Shares forming part of this option was settled by the cancellation of the balance of 9,626 Common Shares, based on the market value of the Common Shares at the time of exercise, and 14,439 Common Shares have been allotted.

 

Block Admission

 

A total of 138,337 new Common Shares have been allotted under the Company's Block Admission of 300,000 Common Shares admitted to AIM on 29 April 2013.

 

Total Voting Rights

 

Following the issue of 138,337 new Common Shares referred to above, the total number of voting rights in the Company's Common Shares is 18,770,117 which may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, MyCelx under the Financial Conduct Authority's Disclosure and Transparency Rules. The Company does not hold any Common Shares in treasury.

 

 

For further information please contact:

 

MyCelx Technologies Corporation

Connie Mixon, CEO

Mark Clark, CFO

Tel: +1 888 306 6843

 

Numis Securities Limited

Corporate Finance

John Prior

Paul Gillam

 

Corporate Broking

James Black

Ben Stoop

Tel: +44 20 7260 1000

 

Bell Pottinger

Nick Lambert

Henry Lerwill

Tel: +44 20 3772 2500

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLFFFIRLISIIE
Date   Source Headline
24th Apr 20247:00 amRNSBusiness Update
11th Apr 20247:00 amRNSEPA Publishes National Drinking Water Standards
26th Mar 20243:30 pmRNSDirector Dealing
26th Mar 20247:00 amRNSDirector Dealing
22nd Mar 20247:00 amRNSDirector Dealing
21st Mar 20247:00 amRNSDirector Dealing
18th Mar 20247:00 amRNSGrant of Share Options to Chief Financial Officer
4th Mar 20247:00 amRNSSaudi Arabia Business Operation Sale Completion
22nd Feb 20247:02 amRNSTrading Update
22nd Feb 20247:00 amRNSSaudi Arabia Business Operation Sale
21st Nov 20237:00 amRNSContract Update
16th Nov 20237:00 amRNSTrading Update
26th Sep 20233:10 pmRNSResult of Annual Meeting
20th Sep 20237:00 amRNSHalf Year Results Statement
11th Jul 20237:00 amRNSContract Award
5th Jul 20233:28 pmRNSHolding(s) in Company
3rd Jul 20232:37 pmRNSContract Award & PFAS Update
21st Jun 20237:00 amRNSMailing of AR and Notice of 2023 Annual Meeting
18th May 20237:00 amRNSFinal Results for the Year Ending 31 December 2022
12th May 20237:00 amRNSHolding(s) in Company
17th Apr 20237:00 amRNSSuccessful leach testing of PFAS media
14th Mar 20234:50 pmRNSClosure of Restricted Stock Line
8th Mar 20237:00 amRNSPilot Testing Agreement for PFAS Remediation
13th Feb 20237:00 amRNSOperational Update
31st Jan 20237:00 amRNSTrading Update
24th Jan 20237:00 amRNSContract Secured for PFAS Remediation System
8th Dec 20227:00 amRNSTrading Update
27th Sep 20227:00 amRNSHalf Year Results Statement
15th Sep 20227:00 amRNSTrading Update
6th Sep 20222:30 pmRNSHolding(s) in Company
30th Aug 20227:00 amRNSNew Project Awards and Operations Update
13th Jul 20223:32 pmRNSResult of Annual Meeting
13th Jun 20227:00 amRNS2021 Annual Report & Notice of 2022 Annual Meeting
17th May 20227:00 amRNSFinal Results for Year Ending 31 December 2021
3rd May 20227:00 amRNSDirector/PDMR Shareholding
3rd May 20227:00 amRNSChange of Main Office Address
23rd Mar 20229:17 amRNSTR1
21st Mar 20225:56 pmRNSBroker Option
16th Mar 20224:09 pmRNSHolding(s) in Company
11th Mar 20221:10 pmRNSDealings by Directors
11th Mar 20227:00 amRNSProposed Placing and Subscription
11th Feb 20227:00 amRNSTrading Update
2nd Feb 202211:07 amRNSHolding(s) in Company
25th Jan 20227:00 amRNSSuccessful Trial of PFAS Remediation System
10th Jan 20227:00 amRNSAward of Green Economy Mark
23rd Nov 20212:36 pmRNSHolding(s) in Company
11th Nov 202111:51 amRNSDealings by Directors
9th Nov 20214:42 pmRNSDirector/PDMR Shareholding
5th Nov 20217:00 amRNSDirector/PDMR Shareholding
28th Oct 20214:34 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.